Q2 2026 EPS Estimates for STERIS plc Boosted by Zacks Research (NYSE:STE)

STERIS plc (NYSE:STE) – Stock analysts at Zacks Research upped their Q2 2026 earnings per share (EPS) estimates for STERIS in a report released on Wednesday, September 25th. Zacks Research analyst R. Department now expects that the medical equipment provider will post earnings of $2.41 per share for the quarter, up from their prior forecast of $2.40. The consensus estimate for STERIS’s current full-year earnings is $9.05 per share. Zacks Research also issued estimates for STERIS’s Q3 2026 earnings at $2.32 EPS.

STERIS (NYSE:STE) last released its quarterly earnings results on Tuesday, August 6th. The medical equipment provider reported $2.14 earnings per share for the quarter, topping analysts’ consensus estimates of $1.98 by $0.16. STERIS had a return on equity of 13.85% and a net margin of 7.36%. The company had revenue of $1.28 billion during the quarter, compared to analysts’ expectations of $1.27 billion. During the same period in the previous year, the firm posted $2.00 earnings per share. The business’s revenue for the quarter was down .4% compared to the same quarter last year.

Other equities research analysts also recently issued research reports about the company. Stephens reaffirmed an “overweight” rating and issued a $260.00 target price on shares of STERIS in a research report on Wednesday, August 7th. JMP Securities restated a “market outperform” rating and set a $265.00 price objective on shares of STERIS in a research note on Wednesday, August 7th. KeyCorp upped their price objective on STERIS from $255.00 to $265.00 and gave the company an “overweight” rating in a research note on Tuesday, September 3rd. Needham & Company LLC reiterated a “hold” rating on shares of STERIS in a research report on Thursday, August 8th. Finally, StockNews.com raised STERIS from a “hold” rating to a “buy” rating in a research note on Tuesday, August 13th. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $246.00.

STERIS Stock Performance

STERIS stock opened at $239.05 on Friday. The firm has a market capitalization of $23.58 billion, a P/E ratio of 62.58 and a beta of 0.83. The stock has a fifty day moving average price of $237.22 and a 200 day moving average price of $225.73. STERIS has a 52 week low of $195.47 and a 52 week high of $248.24. The company has a current ratio of 2.33, a quick ratio of 1.49 and a debt-to-equity ratio of 0.35.

Hedge Funds Weigh In On STERIS

A number of hedge funds have recently modified their holdings of the business. Taylor Frigon Capital Management LLC increased its stake in STERIS by 0.8% in the second quarter. Taylor Frigon Capital Management LLC now owns 6,175 shares of the medical equipment provider’s stock valued at $1,356,000 after purchasing an additional 46 shares in the last quarter. First Hawaiian Bank increased its holdings in shares of STERIS by 0.4% in the 1st quarter. First Hawaiian Bank now owns 13,857 shares of the medical equipment provider’s stock worth $3,115,000 after buying an additional 50 shares during the last quarter. J.Safra Asset Management Corp increased its holdings in shares of STERIS by 77.9% in the 1st quarter. J.Safra Asset Management Corp now owns 121 shares of the medical equipment provider’s stock worth $27,000 after buying an additional 53 shares during the last quarter. Mather Group LLC. increased its holdings in shares of STERIS by 7.6% in the 2nd quarter. Mather Group LLC. now owns 763 shares of the medical equipment provider’s stock worth $172,000 after buying an additional 54 shares during the last quarter. Finally, EverSource Wealth Advisors LLC grew its holdings in shares of STERIS by 16.5% during the 1st quarter. EverSource Wealth Advisors LLC now owns 402 shares of the medical equipment provider’s stock valued at $82,000 after purchasing an additional 57 shares during the last quarter. Institutional investors and hedge funds own 94.69% of the company’s stock.

Insider Buying and Selling at STERIS

In other STERIS news, Director Christopher S. Holland sold 473 shares of the stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $239.68, for a total transaction of $113,368.64. Following the completion of the transaction, the director now owns 582 shares in the company, valued at approximately $139,493.76. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In related news, Director Christopher S. Holland sold 473 shares of the firm’s stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $239.68, for a total value of $113,368.64. Following the completion of the sale, the director now directly owns 582 shares in the company, valued at approximately $139,493.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Michael J. Tokich sold 23,332 shares of the firm’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $247.00, for a total transaction of $5,763,004.00. Following the sale, the chief financial officer now owns 42,930 shares of the company’s stock, valued at $10,603,710. The disclosure for this sale can be found here. Corporate insiders own 1.14% of the company’s stock.

STERIS Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, September 20th. Shareholders of record on Thursday, September 5th were given a dividend of $0.57 per share. This is a boost from STERIS’s previous quarterly dividend of $0.52. The ex-dividend date was Thursday, September 5th. This represents a $2.28 annualized dividend and a dividend yield of 0.95%. STERIS’s payout ratio is presently 59.69%.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.